Agios

Developing Brain Cancer Therapies That Target Metabolic Pathways

Agios Pharmaceuticals is a Boston based biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism.

Groundbreaking research by Agios' scientists established for the first time that the mutated metabolic gene IDH1 has novel enzyme activity consistent with a cancer-causing gene or oncogene.

ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer.  Prior to our involvement, Agios focused exclusively on leukemia research.  Agios now has a drug candidate for low grade gliomas moving into the clinic and have gone on to secure a $250 Million strategic partnering investment from Celgene.

JUNE 2015 UPDATE:  Agios is actively recruiting glioma patients with an IDH1 and/or IDH2 mutation in a Phase I, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881. CLICK HERE for more information.

 

Share |

Join us in our fight for a cure!

Twitter